MEDICAL DEVICE ENTRY
Indonesia Medical Device Company Setup: PT PMA, IDAK, CDAKB, Cost, and Timeline
A product-and-distribution route that separates company formation from distributor readiness, quality controls, and product authorisation.
A foreign investor can use a PT PMA for an Indonesian medical-device business only after the exact role is defined: manufacturer, product-registration holder, importer, distributor, installer, service provider, or a combination. Company incorporation, NIB issuance, an IDAK distributor route, CDAKB quality-distribution compliance and product marketing authorisations are separate workstreams. The correct KBLI, ownership position, technical person, warehouse, quality system, manufacturer mandate and device classification affect what can be submitted and when sales may begin. Core incorporation may finish in weeks, but Kementerian Kesehatan review, facility readiness and device registration can materially extend launch. Capital, service fees, warehouse costs, quality implementation and per-product regulatory costs must be budgeted separately.
Medical Device Entry cost and timeline snapshot
A document-ready PT PMA should plan IDR 56–173 million for first-year external corporate and compliance work. Clean core formation is commonly 10–30 business days; regulated readiness may require 40–70 business days or longer.
The range combines IDR 23–90 million formation, IDR 15–35 million address and IDR 18–48 million compliance. Upfront funding is at least the greater of IDR 2.5 billion equity or the fee-and-working-cash budget; the investment plan is separate. Shareholders or the company pay each recipient at its milestone.
Lean, low-risk
IDR 38 million one-time setup plus IDR 18 million first-year compliance; total IDR 56 million. Keep IDR 2.5 billion equity and the above-IDR-10-billion investment plan separate. Plan 10–20 business days.
Standard, document-ready
IDR 35 million one-time setup including address plus IDR 30 million compliance; total about IDR 65 million. Keep IDR 2.5 billion equity and the above-IDR-10-billion plan separate. Plan 15–30 business days.
Complex or regulated
IDR 73–125 million one-time setup and address plus IDR 48 million compliance; total IDR 121–173 million. Keep IDR 2.5 billion equity, the above-IDR-10-billion plan, sector work and premises separate. Plan 40–70 business days.
Checked August 11, 2026: 2026 PT PMA package and cost benchmarks , independent Indonesia registration timeline benchmark , 2026 accounting and address market ranges and August 10, 2026 USD/IDR market close . Figures exclude VAT and withholding unless stated; they are market estimates, not official tariffs.
Key takeaways
- Choose the PT PMA's regulated role before reserving the company name.
- Foreign ownership depends on the exact KBLI and current investment conditions, not the broad label 'medical devices'.
- An NIB records the business identity; operational certificates and conditions still need their own evidence.
- The critical timeline depends on manufacturer mandate, KBLI confirmation, entity formation, technical-person appointment, facility readiness, IDAK processing, CDAKB evidence and individual product authorisations, not the deed date alone.
- Budget the operating site, licence work, people, tax and bank activation in addition to legal formation.
Confirm the right route for foreign-owned Indonesian medical-device business
Test the proposed activity, cap table, documents and first operating condition for the foreign-owned Indonesian medical-device business before money becomes irreversible.
Choose the manufacturer, importer, or distributor role
A workable medical-device route begins with the real customer promise and the allocation of assets, personnel, funding and authority for a foreign-owned Indonesian medical-device business. Choose the PT PMA's regulated role before reserving the company name. A commercial distributor that will hold IDAK and product responsibilities needs a different operating file from a marketing office that refers sales to an independent authorised distributor. The approved medical-device perimeter controls deed wording, KBLIs, shareholders and project locations. Link medical-device licences, tax and bank evidence before authenticating foreign documents or committing a site.
Draft a one-page medical-device responsibility map for manufacture, import, distribution, marketing, installation, servicing and product-registration roles for each device category. Separate the Indonesian company's work from the foreign group's role, then identify any licensed counterparty and the party bearing medical-device customer liability. Also assess this alternative before commitment: appointing an established authorised Indonesian distributor can be evaluated where the investor does not yet want to own the regulated distribution infrastructure. Define which medical-device evidence or commercial change would require a different KBLI, contract chain or vehicle.
Test foreign ownership and PT PMA capital
Screen medical-device ownership separately for every five-digit KBLI and project location. Foreign ownership depends on the exact KBLI and current investment conditions, not the broad label 'medical devices'. The shareholder arrangement must also support manufacturer appointment, product ownership, quality responsibility and any local technical leadership required by the health-authority pathway. Test the proposed medical-device percentage under Presidential Regulation 10 of 2021, as amended . Then use the live OSS result for medical-device to confirm authority, business scale, location and activity conditions.
The financial plan for a foreign-owned Indonesian medical-device business must keep two numbers apart. Under Minister of Investment/BKPM Regulation 5 of 2025 , the general PT PMA paid-up-capital floor is IDR 2.5 billion per company unless superseded. The medical-device investment plan is generally more than IDR 10 billion for every five-digit KBLI and project location, without counting land and buildings. Paid-up capital is subscribed equity; the other figure describes project scale. Correct any quote that presents either number as an incorporation payment.
For the medical-device business, approve the UBO chain, board appointments, voting and reserved matters. Align signing limits, the funding schedule and the medical-device bank narrative in the same control set. Identify the technical person and quality owner early, then confirm qualifications, availability and responsibility for the proposed product classes. Do not treat a nominee name as a substitute for active supervision, document control and regulator access.
Prepare the corporate, manufacturer, and product dossier
Build the medical-device recipient pack around the real submission needs. Combine the corporate pack with manufacturer authorisations, device classifications, product dossiers, quality procedures, warehouse evidence, responsible technical-person records, distribution agreements and post-market controls. Product and company names must remain consistent across AHU, OSS, IDAK, CDAKB and registration systems. The medical-device master sheet should record names and addresses, identity sources, shares and capital, KBLIs and locations, and authorised signers. Reconcile those medical-device fields across the deed, OSS, tax, bank and sector records at every handoff.
A clean registration path for a foreign-owned Indonesian medical-device business moves from recipient-approved medical-device source records to the notarial deed and Ministry approval under Minister of Law Regulation 49 of 2025 . Filing is handled through AHU corporate services ; OSS projects, the NIB, tax, bank KYC and medical-device sector permissions should then reuse the approved medical-device corporate facts. Final medical-device payment should require custody of originals, credentials, confirmations and a list of unfinished conditions.
For a foreign-owned Indonesian medical-device business, the table should operate as a payment-and-handover schedule rather than a decorative checklist. Each dependency needs a named decision maker, accepted evidence and a stop rule. Scope any Indonesia company registration engagement by outputs—deed, AHU, NIB, tax, licence support, credentials and unresolved matters—so 'complete' has a verifiable meaning.
From corporate approval to first operation
| Stage and decision | Start and owner | Elapsed time and basis | Output and stop-clock |
|---|---|---|---|
| Model: Define manufacturer, holder, importer and distributor roles | Start: Before entity design. Owner: Shareholders, adviser and notary | 4–10 business days for scope and accepted source documents. Checked August 11, 2026; official SLA only where the live service publishes one. | Output: Signed regulatory responsibility map. Stop: inconsistent identity, ownership, activity or authentication data. Rework: +2–10 business days. |
| Company: Form PT PMA with accepted medical-device activities | Start: Ownership and KBLI. Owner: Notary and AHU | 4–10 business days for deed and Ministry formation work. Checked August 11, 2026; official SLA only where the live service publishes one. | Output: Deed, AHU approval, NIB and tax profile. Stop: name, authority, deed data or recipient correction. Rework: +2–10 business days. |
| Facility: Appoint technical owner and implement distribution controls | Start: Product classes. Owner: Director, OSS, tax office and bank | 3–10 business days where OSS, tax and bank steps can overlap. Checked August 11, 2026; official SLA only where the live service publishes one. | Output: Warehouse file and quality procedures. Stop: source-data mismatch, KYC, tax validation or system error. Recovery: +3–20 business days. |
| Market: Obtain entity and product permissions before supply | Start: Complete dossiers and review. Owner: Licence owner and issuing authority | 10–60 business days for sector work; complex review can take longer. Checked August 11, 2026; official SLA only where the live service publishes one. | Output: IDAK, CDAKB evidence and product authorisation. Stop: missing site, technical person, inspection, product or supporting approval. Rework: +5–40 business days or more. |
Sequence IDAK, CDAKB, and product authorisation
Revenue for a foreign-owned Indonesian medical-device business should wait until permission is proved for the exact activity and location. IDAK concerns the medical-device distributor, CDAKB concerns good distribution practice, and product marketing authorisation concerns the device itself. The Ministry of Health's official Regalkes and Info Alkes systems should be used to verify current services, registered products, distributors and implementation notices. The Ministry of Health Regalkes system is the primary current reference for this part of the route and should be checked again against the exact project immediately before submission. Apply Government Regulation 28 of 2025 to the national risk-based framework for medical-device affecting medical-device. Use OSS risk-based licensing system to verify the live medical-device KBLI 2025 risk level, issuing authority and supporting permissions.
Treat medical-device premises as part of the approval route, not as a later property task. Confirm warehouse or distribution-facility suitability, temperature and storage controls, segregation, traceability, complaint handling, recall capability, calibration or servicing needs and any local inspection expectations before the lease becomes unconditional. Record medical-device zoning, building, environment and utilities by site. Track security, data, equipment, inspections and renewals in the same location file; keep acquisition, lease or construction conditional while medical-device feasibility remains open. The medical-device permission tracker should reflect choosing KBLI codes for PT PMA registration where the selected KBLI, location or first transaction creates that dependency.
The medical-device licence owner and operating team must become ready together. Identify the technical person and quality owner early, then confirm qualifications, availability and responsibility for the proposed product classes. Do not treat a nominee name as a substitute for active supervision, document control and regulator access. Before the first live medical-device transaction, test access, signing, escalation and payroll. Test tax, records, complaints, incident response and regulator contact separately. Never assume that a medical-device certificate tied to one person, location or service automatically extends to another. The medical-device permission tracker should reflect business licenses after NIB: when a PT PMA can operate where the selected KBLI, location or first transaction creates that dependency.
Official basis for the medical-device route
Official materials were checked on August 11, 2026 for the cited conclusions. Live OSS, AHU and regulator outputs should still be refreshed immediately before submission.
- Minister of Law Regulation 49 of 2025 — supports the current Ministry of Law company-formation procedure.
- Government Regulation 28 of 2025 — provides the national risk-based business-licensing framework.
- Presidential Regulation 10 of 2021, as amended — provides the national investment-field and foreign-ownership framework.
- Ministry of Health Regalkes system — issues and administers medical-device and household-health product marketing authorisations.
Turn open conditions into an executable plan for foreign-owned Indonesian medical-device business
Keep regulator, institution and counterparty work for foreign-owned Indonesian medical-device business aligned with one controlled source-data file.
Budget quality systems, warehouse, products, and compliance
The budget for a foreign-owned Indonesian medical-device business becomes comparable only when it separates official charges, professional services, equity and project funding, premises and technical permissions, and continuing operations. For a foreign-owned Indonesian medical-device business, use the IDR 23–90 million formation band supported by 2026 PT PMA package and cost benchmarks only as a planning envelope. It excludes paid-up capital, project assets and unquoted sector work. Price the route from named deliverables and acceptance evidence. For the medical-device business, use Government Regulation 30 of 2026 for the current Ministry-of-Law PNBP basis rather than letting a provider blend statutory and commercial amounts.
The variable cost profile for a foreign-owned Indonesian medical-device business is driven by product classification, manufacturer dossier readiness, sworn translation, warehouse fit-out, responsible technical staff, quality-system implementation, IDAK/CDAKB work and the number of product registrations. Require each medical-device proposal to state assumptions, exclusions, third-party disbursements and tax treatment. It must also show medical-device payment milestones, conditional regulator work, completion evidence and refund terms. Reject a low filing price if the resulting medical-device vehicle cannot bank, employ, contract or perform its intended activity.
The deed date is not the completion date for a foreign-owned Indonesian medical-device business. Medical-device market plans often allow two to six weeks for uncomplicated core formation after the documents are accepted, while bank, premises and regulator clocks continue separately. The real critical path runs through manufacturer mandate, KBLI confirmation, entity formation, technical-person appointment, facility readiness, IDAK processing, CDAKB evidence and individual product authorisations. Show a medical-device base case and delay case before signing any date-dependent contract.
Compare owned distribution with an appointed distributor
The structure for a foreign-owned Indonesian medical-device business should survive more than one operating scenario. The medical-device examples below change the asset owner, customer relationship, work location and regulatory role to show when the preferred route also needs to change. Use them to challenge a provider's assumptions before accepting a standard medical-device package.
For a foreign-owned Indonesian medical-device business, the immediate stop conditions include wrong regulated role and product and company files conflict. Pause the next irreversible medical-device payment until the stated controls produce accepted evidence. Do not proceed while medical-device capital, premises, responsible people or operating authority remain unsupported.
How medical-device facts change the route
Own distribution
The group wants direct control of import, inventory, hospital sales and recalls.
Decision: Budget for the PT PMA, technical person, facility, quality system and product-by-product authorisation.
Local distributor route
Demand is uncertain and an established distributor already has the relevant infrastructure.
Decision: Negotiate brand, dossier, registration-holder, data, territory, audit and exit controls before appointment.
Service-only operation
The Indonesian team will install or maintain equipment but not own imported inventory.
Decision: Confirm the service KBLI, workforce competency and product-principal arrangements without assuming distributor permissions.
Risks that block the next medical-device commitment
- Wrong regulated role: Map every party from manufacturer to end user before choosing the KBLI and contracts.
- Product and company files conflict: Use one controlled naming, address and manufacturer-data register.
- Warehouse signed too early: Make the lease conditional on technical and licensing suitability.
Conditions to recheck before the medical-device filing
- The ownership conclusion assumes the stated medical-device activity and location. Re-screen it if the role, site or operator changes.
- An NIB does not override activity, site or sector conditions. Verify the live OSS output and accepting authority's requirements before revenue starts.
- The cited IDR 2.5 billion paid-up-capital floor and investment-plan threshold are general PT PMA rules, not registration fees; sector, concession or financing rules can require more.
Release the first medical-device import and sale
Approve the launch of a foreign-owned Indonesian medical-device business only when the release evidence proves a first shipment and sale supported by the correct importer, distributor, product authorisation, quality records and invoice chain. The medical-device memo should identify the legal entity, approved activities, locations, ownership and authority. It should record medical-device capital, licences, premises and responsible people, plus bank and tax status, open conditions, the evidence owner and review date.
Approve the first transaction only when foreign-owned Indonesian medical-device business is ready
Use a first shipment and sale supported by the correct importer, distributor, product authorisation, quality records and invoice chain as the approval standard, then reconcile every supporting record.
Frequently asked questions
